帮助 关于我们

返回检索结果

Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients

查看参考文献24篇

文摘 Background There is no validated blood biomarker available for glioma management. Invasive growth is the key feature of glioma. We assessed the clinical usefulness of plasma tissue inhibitor of metalloproteinase 1 (TIMP-1), which has less molecular weight than metalloproteinases, as a potential blood biomarker for glioma. Methods A total of 285 patients and 59 normal subjects were studied. Plasma concentration of TIMP-1 was measured with enzyme-linked immunosorbent assay. Plasma TIMP-1 was compared between normal and glioma patients, between patients with different pathological grades, and between patients with different prognoses. Longitudinal changes in plasma TIMP-1 during treatment were also evaluated. Plasma matrix metalloproteinase (MMP)-9 level was also assayed and its clinical usefulness was compared with that of TIMP-1. Results Plasma TIMP-1 and MMP-9 were both increased in glioma patients compared with normal controls (TIMP-1: P <0.001; MMP-9: P=0.007). Plasma TIMP-1 increases with increased tumor grade. In Grade IV gliomas, plasma TIMP-1 significantly increased after “successful removal” of the tumor (paired samples t-test, before operation vs. during chemotherapy without recurrence, t = –2.131, P=0.038), but did not change significantly at the time of tumor recurrence (during chemotherapy without recurrence vs. after tumor recurrence, t = –0.652, P=0.632). High plasma TIMP-1 level correlated with better survival in Grade IV glioma patients (hazard ratio: 0.550, 95% CI: 0.101–1.000, P=0.036). In Grade IV gliomas, patients with higher plasma TIMP-1 had significantly longer survival time than those with lower plasma TIMP-1 level (25.23 vs. 18.95 months, log-rank P=0.045). Plasma MMP-9 did not show significant association with either the pathological grade or the prognosis of glioma patients. Conclusions Plasma TIMP-1 is associated with the diagnosis and prognosis of glioma patients. It appears to have better usefulness for guiding clinical decision making than plasma MMP-9. Further studies in an expanded patient population are needed to better define its clinical usefulness.
来源 Chinese Medical Journal ,2013,126(22):4295-4300 【核心库】
DOI 10.3760/cma.j.issn.0366-6999.20131765
关键词 glioma ; plasma ; biomarker ; tissue inhibitor of metalloproteinase 1 ; metalloproteinase 9
地址

1. Department of Neurosurgery, First Hospital of China Medical University, Liaoning, Shenyang, 110001  

2. Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100050  

3. Harvard Medical School, USA, Boston

语种 英文
文献类型 研究性论文
ISSN 0366-6999
学科 医药、卫生
基金 国家自然科学基金 ;  国家863计划 ;  International Science and Technology Cooperation Program
文献收藏号 CSCD:4983975

参考文献 共 24 共2页

1.  James C D. Molecular biology of central nervous system tumors. Cancer: principles and practice of oncology, 9th ed,2011:1692-1699 被引 1    
2.  Rivera A L. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol,2010,12:116-121 被引 11    
3.  Giannini C. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol,2008,18:360-369 被引 5    
4.  Houillier C. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology,2010,75:1560-1566 被引 21    
5.  Rees J H. Diagnosis and treatment in neuro-oncology: an oncological perspective. Br J Radiol,2011,84(Spec No 2):S82-S89 被引 3    
6.  Iwamoto F M. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol,2011,13:1244-1251 被引 4    
7.  Liu B L. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol,2010,12:540-548 被引 9    
8.  Iwadate Y. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res,2008,28:415-418 被引 2    
9.  Todaro L. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol,2007,83:135-144 被引 3    
10.  Fukuda M E. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res,2005,65:5190-5194 被引 5    
11.  Lin Y. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol,2009,11:468-476 被引 6    
12.  Elstner A. Identification of diagnostic serum protein profiles of glioblastoma patients. J Neurooncol,2011,102:71-80 被引 3    
13.  Lin Y. Increase of plasma IgE during treatment correlates with better outcome of patients with glioblastoma. Chin Med J,2011,124:3042-3048 被引 2    
14.  Lin Y. A panel of four cytokines predicts the prognosis of patients with malignant gliomas. J Neurooncol,2013,114:199-208 被引 1    
15.  Matsukado Y. The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg,1961,18:636-644 被引 1    
16.  Bell E Jr. Cerebral hemispherectomy; report of a case 10 years after operation. J Neurosurg,1949,6:285-293 被引 1    
17.  Clark I M. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol,2008,40:1362-1378 被引 32    
18.  Sato H. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci,2010,101:843-847 被引 13    
19.  Nakano A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg,1995,83:298-307 被引 7    
20.  Forsyth P A. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer,1999,79:1828-1835 被引 19    
引证文献 1

1 Yalcinkaya Emre Determining the combined effect on invasiveness and carcinogenesis process: matrix metalloproteinas/tissue inhibitor of metalloproteinase ratio Chinese Medical Journal,2014,127(6):1196-1196
被引 0 次

显示所有1篇文献

论文科学数据集
PlumX Metrics
相关文献

 作者相关
 关键词相关
 参考文献相关

版权所有 ©2008 中国科学院文献情报中心 制作维护:中国科学院文献情报中心
地址:北京中关村北四环西路33号 邮政编码:100190 联系电话:(010)82627496 E-mail:cscd@mail.las.ac.cn 京ICP备05002861号-4 | 京公网安备11010802043238号